Captodiame or captodiamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H29NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H93K9455DD, chemically known as 2-((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine but generally known as captodiame, which bears US NIH Compound Identifier 10240. Captodiame most often comes in base and hydrochloride forms. European Medicines Agency schedules Captodiame in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06080MIG. The term CAPTODIAME is an International Non-Proprietary Name. World Health Organization schedules captodiame in its Anatomical Therapeutic Chemical (ATC) Classification. CAPTODIAME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Captodiame or captodiamine bears US NLM identifiers UMLS ID C0301409 and NCI Concept Code C81137. SMILES: CCCCSC1=CC=C(C=C1)C(C2=CC=CC=C2)SCCN(C)C.